Horizon Discovery Group PLC - Cambridge-based cell engineering firm - Unveils Cas9 and dCas9-VPR cell lines which can be used to accelerate gene editing workflows. "These stable Cas9 cell lines demonstrate our commitment to making gene editing more accessible and provide the added benefit of decreasing the demand on researchers time, expediting basic research to the target identification and validation phase of the drug discovery pipeline," Product Manager Travis Hardcastle said.
Current stock price: 102.50 pence
Year-to-date change: down 31%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.